TY - JOUR
T1 - Screening for depression in children and adolescents
T2 - US Preventive Services Task Force recommendation statement
AU - On behalf of the US Preventive Services Task Force
AU - Siu, Albert L.
AU - Bibbins-Domingo, Kirsten
AU - Grossman, David C.
AU - Baumann, Linda Ciofu
AU - Davidson, Karina W.
AU - Ebell, Mark
AU - García, Francisco A.R.
AU - Gillman, Matthew
AU - Herzstein, Jessica
AU - Kemper, Alex R.
AU - Krist, Alex H.
AU - Kurth, Ann E.
AU - Owens, Douglas K.
AU - Phillips, William R.
AU - Phipps, Maureen G.
AU - Pignone, Michael P.
N1 - Funding Information:
The US Preventive Services Task Force is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality support the operations of the US Preventive Services Task Force.
Publisher Copyright:
Copyright © 2016 by the American Academy of Pediatrics.
PY - 2016/3
Y1 - 2016/3
N2 - DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).
AB - DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).
UR - http://www.scopus.com/inward/record.url?scp=84960193074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960193074&partnerID=8YFLogxK
U2 - 10.1542/peds.2015-4467
DO - 10.1542/peds.2015-4467
M3 - Article
C2 - 26908686
AN - SCOPUS:84960193074
SN - 0031-4005
VL - 137
JO - Pediatrics
JF - Pediatrics
IS - 3
M1 - e20154467
ER -